Loading...
XASXOSL
Market cap14mUSD
Jan 08, Last price  
0.01AUD
1D
0.00%
1Q
-61.54%
Jan 2017
-94.19%
IPO
-97.22%
Name

Oncosil Medical Ltd

Chart & Performance

D1W1MN
XASX:OSL chart
P/E
—
P/S
14.71
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
21.29%
Rev. gr., 5y
-15.46%
Revenues
2m
+325.75%
01,511,8291,758,3702,063,8682,302,9072,087,124000315,8572,757,1773,837,4223,514,4414,447,7393,626,0822,763,806213,070231,789367,6771,565,383
Net income
-12m
L+5.03%
-26,420-128,266-1,674,138-2,767,299-440,178-1,712,021-1,458,019-430,970-879,168-4,217,103-2,879,031-4,768,598-7,016,079-8,539,542-8,566,731-4,261,895-10,433,523-10,726,703-11,342,926-11,913,632
CFO
-11m
L-4.34%
0195,511-1,345,466-2,180,247-103,974000-471,908-6,369,942-171,159-4,572,568-6,109,845-8,397,341-7,501,154-4,456,079-8,815,401-10,110,178-11,315,634-10,824,337
Earnings
Feb 26, 2025

Profile

OncoSil Medical Limited, a medical device company, focuses on the development and commercialization of localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma in worldwide. Its lead product is OncoSil, a brachytherapy device indicated for the treatment of patients with locally advanced unresectable pancreatic cancer, in combination with gemcitabine-based chemotherapy. The company was formerly known as NeuroDiscovery Limited and changed its name to OncoSil Medical Limited in May 2013. OncoSil Medical Limited was incorporated in 2005 and is headquartered in North Sydney, Australia.
URL
http://www.oncosil.com.au/
IPO date
Aug 15, 2005
Employees
2
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑062015‑06
Income
Revenues
1,565
325.75%
368
58.63%
232
8.79%
Cost of revenue
11,130
12,895
11,710
Unusual Expense (Income)
NOPBT
(9,564)
(12,528)
(11,478)
NOPBT Margin
Operating Taxes
(1,100)
(832)
Tax Rate
NOPAT
(9,564)
(11,428)
(10,647)
Net income
(11,914)
5.03%
(11,343)
5.74%
(10,727)
2.81%
Dividends
Dividend yield
Proceeds from repurchase of equity
6,189
9,675
9,316
BB yield
-69.72%
-67.41%
-22.04%
Debt
Debt current
32
146
165
Long-term debt
109
49
278
Deferred revenue
Other long-term liabilities
(1)
Net debt
(4,360)
(9,198)
(10,837)
Cash flow
Cash from operating activities
(10,824)
(11,316)
(10,110)
CAPEX
(197)
(58)
(6)
Cash from investing activities
(197)
(58)
(6)
Cash from financing activities
6,129
9,487
9,156
FCF
(9,297)
(11,761)
(10,441)
Balance
Cash
4,501
9,394
11,280
Long term investments
Excess cash
4,423
9,375
11,268
Stockholders' equity
4,736
9,880
11,163
Invested Capital
384
676
304
ROIC
ROCE
EV
Common stock shares outstanding
2,219,392
1,196,040
1,056,577
Price
0.00
-66.67%
0.01
-70.00%
0.04
-24.53%
Market cap
8,878
-38.15%
14,352
-66.04%
42,263
-26.11%
EV
4,518
5,154
31,426
EBITDA
(9,520)
(12,352)
(11,351)
EV/EBITDA
Interest
11
20
Interest/NOPBT